WO2005021752A1 - 機能的ヌクレオチド分子の検索方法 - Google Patents
機能的ヌクレオチド分子の検索方法 Download PDFInfo
- Publication number
- WO2005021752A1 WO2005021752A1 PCT/JP2004/012172 JP2004012172W WO2005021752A1 WO 2005021752 A1 WO2005021752 A1 WO 2005021752A1 JP 2004012172 W JP2004012172 W JP 2004012172W WO 2005021752 A1 WO2005021752 A1 WO 2005021752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide sequence
- rna
- protein
- nucleotide
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
Definitions
- the present invention relates to a universal search method for nucleic acids that can effectively suppress gene expression. Further, the present invention relates to a nucleic acid construct and a vector used in the method, and a kit for the method.
- the expression level of a protein is controlled by various methods. For example, by controlling the transcription of mRNA into gene power by transcription factors, controlling the translation of mRNA into amino acid sequence, and controlling the stability of mRNA against degradation of mRNA by nuclease, cells always maintain the target expression level. I control it.
- Methods for artificially suppressing the expression level of a protein at the mRNA stage include suppression of mRNA by antisense RNA, degradation of mRNA by ribozyme, RNAi (RNA interference), and the like.
- RNAi RNA interference
- the inhibitory effects thereof differ significantly depending on which region of the nucleic acid sequence encoding the protein and the surrounding nucleic acid sequence is targeted (for example, Non-Patent Document 1).
- a method of confirming the expression level of a protein a fusion protein of a target protein and a reporter protein is usually synthesized, and the expression level of the protein is estimated using the reporter protein as an index.
- the reporter gene is in a translatable form, and the nucleic acid sequence encoding the adjacent target protein is not translated, and the linked DNA is known.
- Nils en TW et al. Constructed a DNA that expresses a fusion protein in which a target protein and a reporter protein were fused downstream thereof, and examined the expression of the reporter protein to determine the expression of the target nucleic acid sequence.
- the search for ribozymes and the like that can be effectively suppressed is being conducted (for example, Patent Document 1).
- Patent Document 1 it is not easy to express a functional fusion protein, and it is unlikely that the fusion protein will lose its function as a protein due to fusion. Not lost.
- Patent Document 1 US Patent Application Publication No. 2002/0002278
- Non-Patent Document 1 Nature Medicine Vol. 9 No. 3 p. 347 (2003)
- An object of the present invention is to provide a method for searching for a functional nucleotide molecule that changes the expression of a target gene and that can universally correspond to more nucleic acid sequences.
- the present inventors have conducted intensive research and search and have found that the nucleic acid construct has one promoter sequence, at least two gene sequences, and a poly A signal sequence,
- the gene sequence is transcribed as a single molecule of RNA, at least
- nucleic acid construct By constructing a nucleic acid construct in which one gene sequence is in a translatable form and at least one gene sequence is encoded in a substantially untranslated form, it can universally accommodate more nucleic acid sequences, and It has been found that it is possible to search for a molecule that can change the expression of a S-encoding protein that cannot be translated by altering its stability. Furthermore, they have found that the above-described nucleic acid construct can universally cope with more nucleic acid sequences, and have completed the present invention.
- the first invention of the present invention comprises a promoter sequence, a nucleotide sequence 1J encoding at least one protein translatably linked to the sequence, and poly A A nucleic acid construct having a signal sequence,
- the nucleic acid construct contains an untranslated nucleotide sequence between the promoter sequence and the polyA signal sequence that differs from the nucleotide sequence encoding the polypeptide.
- a nucleotide sequence encoding a protein that is translatably linked to a promoter sequence and a nucleotide sequence that is different from the nucleotide sequence that is not translated are linked so as to be transcribed as one molecule of RNA from the nucleic acid construct.
- nucleic acid construct is characterized in that the nucleotide sequence is not selected from the following:
- the nucleic acid construct may be a nucleic acid construct located downstream of a nucleotide sequence encoding a protein translatably linked to a non-translated nucleotide sequence promoter sequence.
- Non-translated nucleotide sequence S promoter
- the nucleic acid construct may be a nucleic acid construct located upstream of a nucleotide sequence encoding a protein translatably linked to one sequence.
- the nucleic acid construct may be a nucleic acid construct in which a nucleotide sequence encoding a protein translatably linked to a promoter sequence encodes a reporter protein.
- the second invention of the present invention relates to a vector containing the nucleic acid construct of the first invention of the present invention.
- a third invention of the present invention relates to an RNA comprising a nucleotide sequence encoding at least one protein in a translatable form and an RNA which is different from the nucleotide sequence and contains a nucleotide sequence which is not translated,
- An RNA wherein the nucleotide sequence is selected from the following:
- a fourth invention of the present invention is a method for detecting an action of changing the expression of a target gene by a functional nucleotide molecule, comprising the following steps:
- nucleotide sequence IJ encoding a protein in the target gene as a nucleotide sequence, a part of the nucleotide sequence, 5 ′ side or 3 ′ side of the nucleotide sequence encoding the protein in the target gene
- step (C) detecting the RNA of step (B) or a translation product translated from the RNA
- step (D) detecting the effect of changing the expression of the target gene by the functional nucleotide molecule based on the amount of the RNA detected in step (C) or the translation product translated from the RNA;
- a fifth invention of the present invention is a method for detecting an effect of changing the expression of a target gene by a functional nucleotide molecule, comprising the following steps:
- (B) a step of detecting the RNA of (A) or a translation product translated from the RNA
- a method for detecting an action that alters the expression of a target gene comprising detecting an action of altering the expression of the target gene by a functional nucleotide.
- a method for detecting the effect of changing the expression of a target gene by a functional nucleotide molecule in which a nucleotide molecule is brought into contact with RNA in a cell or a cell-free protein synthesis system may be used.
- a sixth invention of the present invention is a method for searching for a gene whose expression is changed by a nucleotide molecule, comprising the following steps:
- nucleotide sequence 1J encoding a protein in any gene as a nucleotide sequence, part of the nucleotide sequence, located on the 5 ′ side or 3 ′ side of the nucleotide sequence encoding the protein
- step (D) a step of identifying a gene whose expression is changed by a nucleotide molecule based on the amount of RNA detected in step (C) or a translation product translated from the RNA,
- a seventh invention of the present invention is a method for searching for a gene whose expression is changed by a nucleotide molecule, comprising the following steps:
- nucleotide sequence 1J encoding a protein in any gene as a nucleotide sequence, part of the nucleotide sequence, located on the 5 ′ side or 3 ′ side of the nucleotide sequence encoding the protein
- RNA of the third invention of the present invention having a nucleotide sequence selected from an untranslated region
- (B) a step of detecting the RNA of (A) or a translation product translated from the RNA
- step (C) identifying a functional nucleotide molecule that changes the expression of the target gene based on the amount of the RNA detected in step (B) or a translation product translated from the RNA. Search for genes whose expression changes depending on the characteristic nucleotide molecule About the method.
- FIG. 1 is a view showing a result of a search by a method for searching for a functional nucleotide molecule of the present invention.
- FIG. 2 is a view showing a result of a search by a method for searching for a functional nucleotide molecule of the present invention.
- FIG. 3 is a view showing a result of a search by a method for searching for a functional nucleotide molecule of the present invention.
- FIG. 4 is a view showing a result of a search by a method for searching for a functional nucleotide molecule of the present invention.
- a nucleic acid construct is a construct composed of DNA and / or RNA.
- the nucleic acid construct may be composed of the above-mentioned DNA and RNA analogs or modified compounds, or may be contained in a part thereof.
- target gene refers to a nucleic acid sequence encoding a target protein desired to cause a change in expression, and a nucleic acid sequence at or around Z, and is transcribed from the nucleic acid construct or vector of the present invention. Indicates the sequence that can be performed.
- target nucleic acid sequence or “target nucleic acid sequence” may be used.
- the target gene may be a nucleotide sequence encoding the full length of the target protein or a part thereof, and may be a 5 'UTR (Untranslated Region) or a 3' UTR before or after it. ,. Although it is not particularly limited, for example, in subjects where expression is desired to be suppressed by RNAi action.
- a functional nucleotide molecule such as a base sequence encoding a certain protein and sequences before and after the same (siRNA), and refers to a nucleic acid sequence to be subjected to sequence-specific mRNA degradation via the nucleotide molecule.
- a system IJ corresponding to the exon of the gene and a system J 'modified so as not to contain a sequence functioning as an initiation codon can also be suitably used.
- the target gene may be any of a sequence derived from a eukaryotic organism, a sequence derived from a virus, and a sequence derived from a prokaryotic organism.
- a target gene derived from a virus is useful for searching for a functional nucleotide molecule involved in degradation of the virus genome, replication of the virus, and suppression of growth.
- coding region means a region in a gene consisting of a genetic code that directly defines the amino acid sequence of a protein.
- the term "instability of mRNA” means an increase in the degradation reaction of mRNA.
- the amount of accumulated mRNA is determined by two reactions, synthesis and degradation, but mRNA is destabilized when the balance between the synthesis reaction and the degradation reaction leans toward the degradation reaction.
- the degradation of mRNA is not particularly limited as long as it is degradation of mRNA containing a nucleic acid sequence derived from a target gene, and includes both endless degradation and exolytic degradation.
- a nucleotide molecule refers to a nucleoside phosphate compound.
- the nucleotide molecule may be a ribonucleotide, a deoxyribonucleotide or a chimeric molecule thereof, and may include analogs and modified nucleotides.
- a complex may be formed with proteins, carbohydrates, and the like.
- a functional nucleotide molecule refers to a nucleotide molecule that changes the expression of a protein.
- Functional nucleotide molecules include those that inhibit the expression of the target protein, those that are not translated in the RNA of the invention, those that act sequence-specifically on the nucleotide sequence and ultimately destabilize the entire RNA, Also included are molecules that sequence-specifically degrade untranslated nucleotide sequences in RNA and ultimately destabilize the entire RNA.
- Functional nucleotide molecules may form complexes with proteins, carbohydrates and the like.
- a translatable nucleotide sequence is a nucleotide sequence arranged so that protein synthesis is performed under appropriate conditions and environment. Translation is performed by the cooperation of a number of factors, including the translation initiation signal (translation activator) and translation.
- a form containing a minimum necessary factor for translation such as a translation start codon and a translation stop codon, means a translatable form.
- the term "untranslated nucleotide sequence” refers to a nucleotide sequence which is designed so as not to be theoretically translated, and has a negligible amount even if translated. In other words, it indicates that it is not substantially translated. Even if a very small amount of translation is confirmed, it is equivalent to substantially no translation unless the amount is such as to disregard the feature of the present invention that the effect of the fusion protein can be eliminated. That is, an untranslated nucleotide sequence is a sequence in which the amino acid sequence encoded by the nucleotide sequence and the amino acid sequence encoded by the translatable nucleotide sequence are not translated as a fusion protein. An untranslated form of a nucleotide sequence is a sequence that is not translated due to the lack of minimal translational factors.
- upstream and downstream indicate the positional relationship with respect to the direction in which RNA is transcribed from the promoter of the nucleic acid construct of the present invention.
- one closer to the promoter sequence is upstream, and one closer to the polyA signal sequence is downstream.
- the nucleic acid construct of the present invention is a nucleic acid construct having a promoter sequence, a nucleotide sequence 1J encoding at least one protein translatably linked to the sequence, and a poly A signal sequence,
- the nucleic acid construct contains an untranslated nucleotide sequence different from the nucleotide sequence encoding the polypeptide, between the promoter sequence and the polyA signal sequence,
- a nucleotide sequence encoding a protein that is translatably linked to a promoter sequence and a nucleotide sequence that is different from the nucleotide sequence that is not translated are linked so as to be transcribed as one molecule of RNA from the nucleic acid construct.
- nucleic acid construct is characterized in that the nucleotide sequence not translated is selected from the following.
- a promoter sequence, a poly (A) signal sequence, and a molecule inserted between the promoter sequence and the poly (A) signal sequence are transcribed as one molecule of RNA by the action of the promoter.
- the untranslated nucleotide sequence IJ is derived from a gene different from the translatable nucleotide sequence.
- the nucleic acid construct of the present invention include, but are not limited to, a promoter sequence, a reporter gene sequence, a regulatory IJ functioning as a stop codon, a nontranslated gene, a nucleotide sequence 1J, and a poly A signal sequence. It may be a nucleic acid construct arranged in order.
- a nucleic acid construct may be a nucleic acid construct in which a promoter sequence, a non-translated sequence, a nucleotide sequence, a regulatory IJ functioning as an initiation codon, a reporter gene sequence, and a poly A signal sequence are arranged in this order.
- the untranslated nucleotide sequence (for example, the control gene J derived from the target gene) exists as a UTR of RNA transcribed from the nucleic acid construct and is not translated.
- Nucleotide sequences encoding a translatably linked protein eg, a gene sequence encoding a reporter protein
- a translatably linked protein eg, a gene sequence encoding a reporter protein
- a nucleotide molecule that degrades the region encoding the untranslated nucleotide sequence in the RNA e.g., a ribozyme
- the overall RNA becomes unstable, resulting in reduced expression of the protein encoded by the translatable linked nucleotide sequence. Therefore, by tracking changes in RNA transcribed from the nucleic acid construct of the present invention or a translation product from the RNA, it is possible to universally and easily search for a molecule capable of effectively suppressing the expression of an untranslated nucleotide sequence.
- nucleotide sequence is not translated and the nucleotide sequence is not substantially translated, it may be upstream or downstream of the nucleotide sequence encoding the translatably linked protein. Les ,.
- nucleotide sequence which is not translated may be a sequence derived from a gene different from the nucleotide sequence encoding the protein linked in a translatable form.
- the nucleic acid construct of the present invention is positioned so that the untranslated nucleotide sequence is not translated. It is not particularly limited as long as it does not include a translation start codon (for example, ATG), or it cannot be translated by selecting a specific region, and functions as a start codon that can be used as a form of IJ. If there is a sequence that has the possibility of performing the above, the codon may be modified by performing substitution, addition, deletion, or insertion of base to make the sequence untranslated.
- a translation start codon for example, ATG
- the codon may be modified by performing substitution, addition, deletion, or insertion of base to make the sequence untranslated.
- the nucleic acid construct of the present invention is positioned so that the untranslated nucleotide sequence is not translated. If it is, there is no particular limitation.
- a system 1J (TAA, TAG, TGA) that functions as a stop codon may be arranged between a nucleotide sequence encoding a protein that is linked in a translatable form and a nucleotide sequence that is not translated.
- RNA three consecutive base reading frames (codons) from the start codon of the nucleotide sequence encoding the translatably linked protein define the stop codon, and this stop codon allows translation of RNA. Stop at a protein that is linked in an unusual manner, and the downstream untranslated nucleotide sequence is not translated.
- a translatablely linked protein that is not translated into a nucleotide sequence encoding a translatably linked protein and that does not produce a fusion protein of the protein encoded by the nucleotide sequence.
- the translation product of the nucleotide sequence encoding the Park protein can be expected to be expressed while reflecting the stability of the m RNA.
- the nucleic acid construct of the present invention can be used in a method for detecting a change in gene expression due to a functional nucleotide molecule.
- the promoter sequence contained in the nucleic acid construct of the present invention may be a sequence having an activity related to the transcription initiation reaction of RNA in an eukaryotic cell or an environment similar thereto (eg, a cell-free protein expression system).
- Promoter sequences derived from eukaryotic organisms eg, ⁇ -actin promoter, U6 promoter
- promoter sequences derived from viruses that have a promoter activity in eukaryotic cells eg, CMV (cytomegalovirus) Promoter
- CMV cytomegalovirus
- a promoter sequence derived from a eukaryotic organism or a virus as well as a promoter sequence derived from a virus, or a phage derived from a phage such as ⁇ ⁇ ⁇ ⁇ 7 A promoter sequence may be selected.
- a promoter that constantly expresses strongly when searching for a functional nucleotide molecule that suppresses protein expression, a promoter that constantly expresses strongly can be preferably used so that the extent of the suppression can be clearly determined.
- the nucleotide sequence encoding the translatably linked protein contained in the nucleic acid construct of the present invention includes a reporter gene sequence.
- the reporter gene sequence is not limited as long as it is a nucleic acid sequence of a gene encoding any protein that can be detected directly and / or indirectly.
- the protein encoded by the reporter gene is not particularly limited, but may be an enzyme that produces a specifically detectable substance such as j3-galactosidase, luciferase, alkaline phosphatase, or an enzyme that is directly detected. Examples of such proteins are:
- the reporter gene may be used by selecting only a part of the reporter gene within a range that retains its useful characteristics.
- a combination of a plurality of reporter genes may be used.
- Methods for direct protein detection include detection using a specific antibody that recognizes the reporter protein, and reporter proteins that generate a fluorescent signal, such as green fluorescent protein (GFP). Examples include a method for detecting fluorescence, and a selectable marker protein that confers a drug resistance trait. Cells can be sorted by these reporter proteins. For example, in the case of a reporter protein that generates a fluorescent signal, cells expressing the protein can be selected by FACS (fluorescence activated cell sorting) method, which is useful.
- FACS fluorescence activated cell sorting
- the untranslated nucleotide sequence contained in the nucleic acid construct of the present invention may be a region of a target gene of interest (for which it is desired to change the expression), or may be a region of deviation, and may encode a target protein.
- the region, a part of the coding region, the 3 ′ UTR, and the 5 ′ UTR can all be selected as nucleotide sequences without translation.
- the nucleotide sequence which is not translated may be a sequence derived from a plurality of genes.
- nucleic acid (s) generated from genomic libraries, cDNA libraries, cDNA libraries expressed at specific organs, and stages derived from the organism of interest can be used as untranslated nucleotide sequences. .
- the nucleic acid construct of the present invention can be used in a host cell or a transcription reaction solution into which the nucleic acid construct has been introduced.
- RNA may be destabilized by a functional nucleotide molecule.
- a functional nucleotide molecule includes a molecule that recognizes and acts on a nucleotide sequence region of RNA that has not been translated and that recognizes the base sequence of the region, thereby destabilizing the entire RNA.
- dsRNA for example, dsRNA, siRNA, shRNA, nuclease complex (RISC) in the RNAi mechanism, stRNA (small temporal RNA) which is thought to be involved in the developmental stage of organisms, and MiRNA (microRNA), protein complex containing miRNA, miRNP, ribozyme, maxizim, hammerhead ribozyme, antisense RNA, EGS (External Guide Sequence), and tamper containing these nucleotide molecules.
- RISC nuclease complex
- miRNA small temporal RNA
- MiRNA microRNA
- protein complex containing miRNA miRNP
- ribozyme protein complex containing miRNA
- maxizim miRNA
- hammerhead ribozyme maxizim
- antisense RNA EGS (External Guide Sequence)
- EGS Extra Guide Sequence
- tamper containing these nucleotide molecules.
- RNA transcribed from the nucleic acid construct of the present invention a nucleotide sequence encoding a translatably linked protein such as a reporter protein is not converted into a fusion protein, but in a state close to nature as a single protein. Stably expressed. Therefore, in the method for detecting gene expression of the present invention, for example, the reporter protein When expression is suppressed, it is possible that this phenomenon may be caused by a change in the original function of the reporter protein due to the fusion of the protein encoded by the target gene and the reporter protein. Can be eliminated. In addition, functional nucleotide molecules are not translated, and the nucleotide sequence acts to inhibit the translation mechanism, eliminating the possibility that this is a phenomenon caused by a change in the original function of the reporter protein. be able to.
- nucleic acid construct of the present invention does not have to match the reading frame such as selecting an appropriate restriction enzyme recognition site or inserting or deleting a base, so that the nucleic acid construct is translatably linked to an untranslated nucleotide sequence. Nucleotide sequences encoding the encoded proteins are easily linked.
- a nucleic acid construct having a nucleotide sequence encoding a translatably linked protein and a restriction enzyme recognition cleavage site adjacent thereto is not translated into the restriction enzyme recognition cleavage site.
- the nucleotide sequence encoding the protein which is linked in a translatable manner is not translated from the nucleic acid construct, and the nucleotide sequence is substantially translated.
- Nucleic acid constructs in which the encoded RNA is transcribed are also included in the nucleic acid constructs of the present invention. The nucleic acid construct is useful because the target gene sequence can be freely inserted according to the purpose when used.
- the restriction enzyme recognition cleavage site may be any sequence convenient for inserting the target gene sequence of interest. Although not particularly limited, for example, a sequence in which one or more restriction enzyme sites called a cloning site and a multiple cloning site are arranged, and a sequence widely used in commercially available vectors, linkers, and the like are preferable. Can be used for
- the poly A signal sequence is a sequence that causes a poly A addition reaction at the 3 'end of mRNA.
- the poly A signal sequence is not particularly limited as long as it is a sequence that causes a poly A addition reaction.
- the AAUAAA nucleotide sequence which is highly conserved in higher eukaryotic mRNAs and is usually located 11 to 30 bases upstream of the polyA-added site, is No.
- one terminator sequence may be arranged downstream of the poly A signal sequence.
- the terminator sequence may be any sequence as long as it has a function of terminating transcription of mRNA by RNA polymerase. Without limitation, in higher eukaryotes, RNA polymerase terminates RNA synthesis at multiple sites within a terminator sequence.
- the poly A signal sequence and terminator sequence contained in the nucleic acid construct of the present invention can be appropriately selected according to the environment in which the RNA transcription reaction is performed.
- a large number of protein expression vectors are commercially available depending on the host, and the nucleic acid construct of the present invention may be prepared based on these vectors or by combining them.
- a PGH-derived BGHpolyA signal distribution IJ and a terminator sequence can be used.
- the vector of the present invention is a vector containing the nucleic acid construct of the present invention.
- a translatably linked protein represented by a reporter gene sequence is linked. Any vector may be used as long as it encodes the nucleotide system 1J, the untranslated gene represented by the target gene sequence, the nucleotide system IJ, and the RNA containing the polyA signal sequence in the same molecule. Further, a vector used for producing the vector of the present invention is also included in the vector of the present invention as long as it contains the nucleic acid construct of the present invention.
- the vector of the present invention may be any of a plasmid vector, a phage vector, a vector capable of autonomous replication, a virus vector, a vector integrated into a host chromosome, and a vector which is transiently or transiently expressed. It is preferable to select a suitable species-derived vector and host depending on the promoter sequence, gene sequence, and functional nucleotide molecule contained in the nucleic acid construct of the present invention. At present, many host vector systems are commercially available and can be appropriately selected depending on the purpose.
- the RNA of the present invention is an RNA containing a nucleotide sequence encoding at least one protein in a translatable form and a nucleotide sequence different from the nucleotide sequence, which is different from the nucleotide sequence.
- RN characterized in that the nucleotide sequence is selected from: A;
- RNA of the present invention can be prepared by transcribing the nucleic acid construct of the present invention in vivo or in vivo.
- RNA of the present invention can be used in the method of searching for a functional nucleotide molecule that changes the expression of the target gene of the present invention, and the method of searching for a gene whose expression changes depending on the nucleotide molecule.
- the method for detecting the action of the functional nucleotide molecule of the present invention to alter the expression of a target gene comprises the following steps:
- step (C) detecting the RNA of step (B) or a translation product translated from the RNA
- step (D) detecting the effect of changing the expression of the target gene by the functional nucleotide molecule based on the amount of the RNA detected in step (C) or the translation product translated from the RNA;
- a method for detecting an action that alters the expression of a target gene, characterized by comprising is there.
- One embodiment of the method for searching for a functional nucleotide molecule of the present invention includes a method for searching for a functional nucleotide molecule, which includes the following steps.
- the nucleic acid construct or vector of the present invention namely, the promoter system 1J, the poly-A signal sequence, and the transcription inserted as one molecule of RNA by the action of the promoter inserted between the promoter sequence and the poly-A signal sequence
- a nucleic acid construct having the DNA sequence to be prepared or a vector containing the nucleic acid construct is prepared.
- the DNA sequence is a DNA sequence having an untranslated nucleotide sequence connected to the reporter gene sequence, and the reporter gene product is in a translatable form and the nucleotide sequence is not translated from the DNA.
- the DNA sequence from which the encoded RNA is transcribed.
- RNA is transcribed using the nucleic acid construct or vector of (A).
- a series of a nucleotide sequence 1J encoding a protein translatably linked by using the nucleic acid construct of the present invention or a vector containing the nucleic acid construct, a sequence that is not translated, a nucleotide sequence, and a polyA signal sequence RNA containing the above sequence is transcribed, or RNA of the present invention is prepared, and this RNA is brought into contact with a nucleotide molecule to form a portion corresponding to a nucleotide sequence encoding a protein which is linked in a translatable form of RNA.
- translated proteins can be detected and compared to detect the effect of the functional nucleotide molecule on the expression of the target gene.
- the nucleotide causing the change is a functional nucleotide.
- the transcription of the RNA, the contact with the nucleotide molecule, and the expression of the protein may be performed in a cell or outside the cell, or may be performed in parallel or sequentially.
- the method for searching for a functional nucleotide molecule is not particularly limited.
- a nucleic acid construct of the present invention or a vector of the present invention is introduced into a host cell with a functional nucleotide molecule and ligated in a translatable form.
- the expression of the nucleotide sequence encoding the protein may be confirmed.
- the functional nucleotide molecule is designed to be produced in a host cell which can be chemically synthesized or biosynthesized based on the target nucleic acid sequence IJ or a part thereof.
- the product may be a product obtained by introducing a vector into a host cell and expressing it in the cell.
- the functional nucleotide molecule may be of a plurality of types, and may be a plurality of nucleotides derived from a genomic library, a cDNA library, or an organ'stage-specific cDNA library. By using such a library, a functional nucleotide molecule that changes the expression of the target gene can be screened.
- a nucleotide molecule is contacted with RNA transcribed from the nucleic acid construct or vector of the present invention or the RNA of the present invention, and the RNA after the contact is directly detected or a translation product of the RNA is detected.
- RNA transcribed from the nucleic acid construct or vector of the present invention or the RNA of the present invention is directly detected or a translation product of the RNA is detected.
- Many methods have been reported for directly detecting RNA, but any method that can qualitatively or quantitatively detect RNA can be used.
- concentration measurement concentration measurement, gel electrophoresis, PCR (Polymerase Cham Reaction), l> zo'noretam PT-PCR, TA3 ⁇ 4 (Transcription-based Amplification System), 3SR (Self- sustained Sequence Replication), NASBA (Nucleic Acid Sequence-Based Amplification) method, Qi3 replicase method, and TMA (Transcription Mediated Amplification) method.
- a method for introducing a nucleic acid construct capable of producing the nucleic acid construct of the present invention, the vector of the present invention, a functional nucleotide molecule, or a functional oligonucleotide molecule into a host cell is a suitable method depending on the nucleic acid construct and the vector. There is no particular limitation as long as it is selected, but it may be directly introduced physically or chemically, or may be introduced by infection.
- the method for searching for a gene whose expression is changed by the nucleotide molecule of the present invention comprises the following steps:
- A a nucleotide sequence encoding a protein in any gene as a nucleotide sequence which is not translated, a part of the nucleotide sequence, located on the 5 ′ side or 3 ′ side of the nucleotide sequence encoding the protein R from the nucleic acid construct of the first invention of the present invention or the vector of the second invention of the present invention having a nucleotide sequence selected from the untranslated region.
- step (D) identifying a gene whose expression is changed by a nucleotide molecule based on the amount of RNA detected in step (C) or a translation product translated from the RNA,
- a method for searching for a gene whose expression is changed by a nucleotide molecule characterized by comprising:
- a method in which a plurality of target sequences derived from a genomic library, a cDNA library, or an organ stage-specific cDNA library are prepared as untranslated nucleotide sequences A nucleic acid construct or a vector of the present invention is prepared, a plurality of RNAs including a plurality of untranslated RNAs or nucleotide sequences are transcribed, or a plurality of RNAs of the present invention are prepared, and a functional nucleotide is added to the RNA.
- a gene whose expression is altered by the functional nucleotide molecule can be screened.
- the function of the functional nucleotide molecule can be searched.
- the method includes a promoter system IJ, a poly A signal system IJ, and a nucleic acid having a DNA sequence inserted between the promoter sequence and the poly A signal sequence and transcribed as one molecule of RNA by the action of the promoter. Constructs can be suitably used.
- the DNA sequence is a DNA sequence having a reporter gene sequence and a restriction enzyme recognition and cleavage site adjacent thereto, and when the target gene sequence is inserted into the restriction enzyme recognition and cleavage site, a reporter gene is generated from the DNA.
- the product derived from the target gene sequence is a DNA sequence from which the encoded RNA is transcribed in a translatable form and the product derived from the target gene sequence is not translated.
- the present invention provides a kit for use in the method for searching for a functional nucleotide molecule of the present invention exemplified in the above (4) and (5), and the method for searching for a gene whose expression is changed by a nucleotide molecule. .
- the nucleic acid construct of the present invention in packaged form, as set forth in (1) above, or no translation in the nucleic acid construct.
- the kit of the present invention also includes a kit containing a nucleic acid construct that allows a user to insert a sequence derived from a desired target gene by replacing the gene sequence with a cloning site instead of the cloning site. Further, the kit of the present invention may include an instruction.
- the "instructions” are printed materials that describe how to use the kit, for example, how to prepare a reagent solution, recommended reaction conditions, and the like. Includes those attached to the attached label and the package containing the kit. It also includes information disclosed and provided through electronic media such as the Internet.
- the kit of the present invention includes a kit containing the vector shown in the above (2) and the RNA shown in the above (3).
- the cells were aerobically cultured at 37 ° C using an LB-ampicillin plate to which agar was added and solidified.
- the cells were cultured using Dulbecco's modified Eagle's medium (Bio-Itakane earth) plus 10% fetal serum (Bio-Wita) as a medium, and inoculated into a Petri dish for cell culture (Iwaki Glass).
- the test was performed in the incubator. Use of the kit and handling of various devices were performed according to the attached instruction manual.
- Plasmid PQBI25 (manufactured by Wako Chemicals USA) has CMV promoter, rsGF red shredded Green Fluoresence Protem, and BGHpolyA, and expresses rsGFP efficiently in Itoda cells. Restriction enzyme between rsGFP gene and BGHpolyA The sites BamHI and EcoRI are present.
- DsDNA (SEQ ID NO: 1 in the sequence listing) with restriction enzymes BamHI and EcoRI cohesive ends added to both ends of the sequence from the 75 bases downstream of the start codon of the mouse Fas gene (GenBank Accession: M83649) to the stop codon, BamHI of PQBI25,
- the target plasmid pTargetFas was constructed by inserting into the EcoRI site.
- the target plasmid transcribes RNA containing the rsGFP gene sequence and a partial sequence of the Fas gene in the cell.
- RNA2-1 SEQ ID NO: 2
- RNA2-2 SEQ ID NO: 3
- RNA3-1 SEQ ID NO: 4
- RNA3-2 SEQ ID NO: 5
- RNA3, RNA4-1 Anneal RNA4, RNA5-1 (SEQ ID NO: 8) and RNA5-2 (SEQ ID NO: 9)
- RNA5 Anneal RNA4
- RNA4-2 Anneal RNA5-1 (SEQ ID NO: 8)
- RNA5-2 SEQ ID NO: 9
- RNA6 SEQ ID NO: 10
- RNA6-2 SEQ ID NO: 11
- dsRNA was introduced into 293 cells (ATCC No: CRL_1573) together with pTargetFas. Gene transfer was carried out using Lipofectamine 2000 (Invitrogen) and Ribojuice (Takara Bio Inc.). After culturing the cells for 2 days, the cells were detached from the petri dish using trypsin, and the fluorescence intensity of the cells was measured using MoFlo (manufactured by Takara Bio Inc.). The results are shown in Figure 1.
- FIG. 1 shows relative values when the fluorescence intensity of cells into which RNA was not introduced was set to 100 as a control. Cells into which RNA2 and pTarget Fas were introduced had the lowest fluorescence intensity, and thus it was determined that RNA2 was siRNA that effectively suppressed the expression of the Fas gene.
- RNA2, RNA3, RNA4, RNA5 and RNA6 were introduced into NIH3T3 cells (ATCC No: CRL_1658) expressing Fas using Ribojuice (Takara Bio Inc.). Two days later, these cellular RNAs were extracted, and Fas mRNA was quantified by real-time RT-PCR. As a control, cells into which RNA had not been introduced were used, and a rat for housekeeping gene GAPD H (Glyceraldehyde-3-phosphate dehydrogenase) was used to perform a negative reaction.
- GAPD H Glyceraldehyde-3-phosphate dehydrogenase
- Real-time RT-PCR is a real-time RT-PCR core kit (Takara Bio Inc.) Using the Smart Cycler System (manufactured by Takara Bio Inc.), oligo DNAs of SEQ ID NOS: 12 and 13 as Fas primers and Real time R T-PCR primer (manufactured by Takara Bio Inc.) as primers for GAPDH ) Were used. The result is shown in figure 2.
- FIG. 2 shows a relative value when the amount of mRNA of a cell into which no RNA was introduced was set to 100 as a control. The decrease in the amount of Fas mRNA was consistent with the decrease in the fluorescence intensity of rsGFP obtained in Example 2, confirming that the screening method was useful.
- rsGFP-1 SEQ ID NO: 14
- rsGFP_2 SEQ ID NO: 15
- a fragment SEQ ID NO: 16
- This DNA fragment was treated with the restriction enzymes Xbal and Nhel, and a DNA fragment of about 720 bp was inserted into the restriction enzyme site Xbal between the firefly luciferase gene of the plasmid pGL3control (Promega) and SV4 OpolyA.
- the target plasmid pGL3_3 ′ was constructed.
- RNA7-1 Toshimi column No. 17
- RNA7-2 SEQ ID NO: 18
- RNA8-1 SEQ ID NO: 19
- RNA8-2 SEQ ID NO: 20
- RNA9 RNA9 RNA10-1
- RNA10-2 SEQ ID NO: 24
- dsRNAs were introduced into 293 cells (ATCC No: CRL_1573) together with pGL3-3 '(GFP) and pRL_TK (Promega) expressing P. mushroom luciferase as an internal control.
- Gene transfer was performed using TransIT293 (manufactured by Takara Bio Inc.) and TransIT-TKO (manufactured by Takara Bio Inc.).
- the siRNA concentration was determined so that the final concentration was 1.25-160 nM. After culturing the cells for 24 hours, the culture supernatant was removed, and the cells were washed once with PBS, and lysed with 5X Passive Lysis Buffer (Promega) diluted 5-fold with deionized water.
- the horizontal axis represents the siRNA concentration at the time of transfection
- the vertical axis represents the force without RNA transfection as a control
- FIG. 3 shows that the relative values of the relative luminescence intensities show lower values in the order of RNA8, RNA10, RNA9, and RNA7. From this, it was determined that the siRNA was a siRNA that effectively suppressed the expression of the rsGFP gene in the order of RNA8, RNA10, RNA9, and RNA7.
- siRNA7-10 and rsGFP expression plasmid (pQBI25) was introduced into 293 Itoda vesicles using TransIT 293 and TransIT-TKO. Two days later, the cell strength and RNA were extracted, and rsGFP mRNA was quantified by real-time RT-PCR. As a control, cells transfected with pQBI25 alone were used, and the data were corrected using the neomycin resistance gene on pQBI25.
- Real-time RT-PCR was performed using a real-time RT-PCR core kit (manufactured by Takara Bio Inc.) and a smart cycler system (manufactured by Takara Bio Inc.), and GFP_B_F (SEQ ID NO: 25) and GFP_B_R (SEQ ID NO: 26) were used as primers for rsGFP.
- GFP_B_F SEQ ID NO: 25
- GFP_B_R SEQ ID NO: 26
- Fig. 4 shows the results. In FIG.
- the horizontal axis represents the name of the siRNA used, and the vertical axis represents the relative value when the amount of mRNA of cells into which only pQBI25 was introduced as 100 was taken as a control.
- the siRNA search method described in Examples 45 is useful. Was confirmed.
- the present invention provides a method for searching for a nucleotide molecule that can universally cope with a larger number of target genes and suppresses the expression of target genes by destabilizing RNA. Sequence listing free text
- SEQ ID NO: 2 Chimeric oligonucleotide designed as RNA2—1. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides "
- SEQ ID N ⁇ : 3 Chimeric oligonucleotide designed as RNA2-2. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 4 Chimeric oligonucleotide designed as RNA3-1. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID N ⁇ : 5 Chimeric oligonucleotide designed as RNA3-2. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID N ⁇ : 6 Chimeric oligonucleotide designed as RNA 4-1. “Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides”
- SEQ ID NO: 7 Chimeric oligonucleotide designed as RNA4-2. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID N ⁇ : 8 Chimeric oligonucleotide designed as RNA 5-1. “Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides”
- SEQ ID N ⁇ : 9 Chimeric oligonucleotide designed as RNA5—2. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID N ⁇ : 10 Chimeric oligonucleotide designed as RNA6-1. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID N ⁇ : l l Chimeric oligonucleotide designed as RNA6-2.
- Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides
- SEQ ID NO: 12 Designed PCR primer to amplify a portion of mouse Fas gene.
- SEQ ID N ⁇ : 13 Designed PCR primer to amplify a portion of mouse Fas gene.
- SEQ ID N ⁇ : 14 Designed PCR primer rsGFP-l to amplify a portion of rsGFP gene.
- SEQ ID N ⁇ : 15 Designed PCR primer rsGFP-2 to amplify a portion of rsGFP gene.
- SEQ ID NO: 16 rsGFP gene
- SEQ ID NO: 17 Chimeric oligonucleotide designed as RNA7-1.
- Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID N ⁇ : 18 Chimeric oligonucleotide designed as RNA7-2.
- Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID N ⁇ : 19 Chimeric oligonucleotide designed as RNA8-1. "Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 20 Chimeric oligonucleotide designed as RNA8-2.
- ⁇ nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 21 Chimeric oligonucleotide designed as RNA9-1.nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 22 Chimeric oligonucleotide designed as RNA9-2.nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 23 Chimeric oligonucleotide designed as RNAlO-l.
- Nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 24 Chimeric oligonucleotide designed as RNA10-2.nucleotides 1 to 19 are ribonucleotides-other nucleotides are deoxyribonucleotides ⁇
- SEQ ID NO: 25 Designed PCR primer GFP—B—F to amplify a portion of rsGFP gens.
- SEQ ID NO: 26 Designed PCR primer GFP—B—R to amplify a portion of rsGFP gens.
- SEQ ID NO: 27 Designed PCR primer Neo_F to amplify a portion of neomycin resistant gene.
- SEQ ID NO: 28 Designed PCR primer Neo-R to amplify a portion of neomycin resistant gene.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513439A JPWO2005021752A1 (ja) | 2003-08-29 | 2004-08-25 | 機能的ヌクレオチド分子の検索方法 |
US10/569,814 US20070077563A1 (en) | 2003-08-29 | 2004-08-25 | Method of searching for functional nucleotide molecule |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-307624 | 2003-08-29 | ||
JP2003307624 | 2003-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005021752A1 true WO2005021752A1 (ja) | 2005-03-10 |
Family
ID=34269450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012172 WO2005021752A1 (ja) | 2003-08-29 | 2004-08-25 | 機能的ヌクレオチド分子の検索方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070077563A1 (ja) |
JP (1) | JPWO2005021752A1 (ja) |
KR (1) | KR20060065693A (ja) |
CN (1) | CN1875103A (ja) |
TW (1) | TW200519200A (ja) |
WO (1) | WO2005021752A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1575574A2 (en) * | 2002-10-30 | 2005-09-21 | The Center for Blood Research, INC. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1601264A1 (en) * | 2003-03-10 | 2005-12-07 | Rancangelo di Rancan Dario e Pietro S.N.C. | Method for the production of elongated elements for jewels |
FR3026409B1 (fr) * | 2014-09-26 | 2018-03-30 | Centre National De La Recherche Scientifique (Cnrs) | Procede de criblage de molecules interferentes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004509A2 (de) * | 2000-07-11 | 2002-01-17 | Cell Center Cologne Gmbh | Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen |
WO2002016944A2 (en) * | 2000-08-24 | 2002-02-28 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
WO2002034940A2 (en) * | 2000-10-26 | 2002-05-02 | Xenon Genetics Inc. | Methods for screening compounds that modulate lipid metabolism |
WO2004076629A2 (en) * | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020002278A1 (en) * | 1999-11-05 | 2002-01-03 | Timothy W. Nilsen | Random intracellular method for obtaining optimally active nucleic acid molecules |
-
2004
- 2004-08-25 US US10/569,814 patent/US20070077563A1/en not_active Abandoned
- 2004-08-25 JP JP2005513439A patent/JPWO2005021752A1/ja active Pending
- 2004-08-25 KR KR1020067003181A patent/KR20060065693A/ko not_active Application Discontinuation
- 2004-08-25 WO PCT/JP2004/012172 patent/WO2005021752A1/ja active Application Filing
- 2004-08-25 CN CNA200480032070XA patent/CN1875103A/zh active Pending
- 2004-08-27 TW TW093125887A patent/TW200519200A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004509A2 (de) * | 2000-07-11 | 2002-01-17 | Cell Center Cologne Gmbh | Genexpression, genomalteration und reporterexpression in myofibroblasten und myofibroblast-ähnlichen zellen |
WO2002016944A2 (en) * | 2000-08-24 | 2002-02-28 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
WO2002034940A2 (en) * | 2000-10-26 | 2002-05-02 | Xenon Genetics Inc. | Methods for screening compounds that modulate lipid metabolism |
WO2004076629A2 (en) * | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
Non-Patent Citations (2)
Title |
---|
DOENCH J.G. ET AL.: "siRNAs can function as miRNAs", GENES. DEV., vol. 17, no. 4, 15 February 2003 (2003-02-15), pages 438 - 442, XP002982608 * |
YOKOTA T. ET AL.: "Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs", EMBO REP., vol. 4, no. 6, June 2003 (2003-06-01), pages 602 - 608, XP002300964 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1575574A2 (en) * | 2002-10-30 | 2005-09-21 | The Center for Blood Research, INC. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
EP1575574A4 (en) * | 2002-10-30 | 2007-11-07 | Blood Res Center | METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005021752A1 (ja) | 2007-11-01 |
CN1875103A (zh) | 2006-12-06 |
KR20060065693A (ko) | 2006-06-14 |
TW200519200A (en) | 2005-06-16 |
US20070077563A1 (en) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7759478B1 (en) | Bioinformatically detectable viral regulatory genes | |
Letzring et al. | Control of translation efficiency in yeast by codon–anticodon interactions | |
CA2678055C (en) | Rna interference tags | |
AU2014369175B2 (en) | Novel eukaryotic cells and methods for recombinantly expressing a product of interest | |
Ellis et al. | A cis-encoded sRNA, Hfq and mRNA secondary structure act independently to suppress IS 200 transposition | |
Retallack et al. | Persistence of ambigrammatic narnaviruses requires translation of the reverse open reading frame | |
US11713460B2 (en) | Protecting RNAs from degradation using engineered viral RNAs | |
US20110003883A1 (en) | Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline | |
WO2005021752A1 (ja) | 機能的ヌクレオチド分子の検索方法 | |
US20040181821A1 (en) | siRNA research tool kit | |
WO2006130976A1 (en) | Interfering rnas, methods for their production, and use | |
Tripp et al. | Therapeutic applications of RNAi for silencing virus replication | |
JP5139067B2 (ja) | shRNA発現のための有効な新規ループ配列 | |
US8148144B2 (en) | pCryptoRNAi | |
JP2017528151A (ja) | 干渉性分子のスクリーニング方法 | |
CN112877360B (zh) | 一种检测ires活性的环rna荧光素酶报告质粒构建方法 | |
US7504492B2 (en) | RNA polymerase III promoter, process for producing the same and method of using the same | |
WO2006006520A1 (ja) | 新規創薬標的の探索方法 | |
Brandt | Design, Synthesis and Delivery of a Self-Cleaving Replicon System Yielding Biologically Active MicroRNAs in vivo | |
CN106978417B (zh) | 一种HuR蛋白可识别的RNA片段及在HuR活性检测中的应用 | |
Bak et al. | An effective method for specific gene silencing in Escherichia coli using artificial small RNA | |
Apura et al. | Tailor-made sRNAs: a toolbox to control metabolic targets | |
US9777277B2 (en) | Organic small hairpin RNAs | |
CN115491377A (zh) | 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用 | |
Martin | Developing an RNAi based approach to silence the expression of HMGAI proteins in human mammalian epithelial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480032070.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513439 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067003181 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007077563 Country of ref document: US Ref document number: 10569814 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067003181 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10569814 Country of ref document: US |